BioComo
Kobe, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Japanese biotech developing intranasal spray vaccines using a proprietary human parainfluenza virus vector platform for respiratory infections and cancer.
Infectious DiseaseOncology
Technology Platform
Proprietary human parainfluenza virus (hPIV) vector platform that combines high cell adhesion properties of live viruses with enhanced safety features of inactivated viruses for intranasal vaccine delivery.
Opportunities
Growing demand for non-invasive vaccine delivery methods and mucosal immunity approaches, particularly for respiratory pathogens where intranasal administration could provide superior protection at infection sites.
Risk Factors
Preclinical stage company facing significant development risks, intense competition in both RSV and COVID-19 vaccine markets from established pharmaceutical companies, and potential challenges in scaling manufacturing for viral vector platforms.
Competitive Landscape
Competes with major vaccine developers like GSK, Pfizer, and Moderna in RSV, and numerous companies in COVID-19, but differentiates through intranasal delivery and hPIV vector technology targeting mucosal immunity.